Charles River Laboratories International Balance Sheet Health
Financial Health criteria checks 4/6
Charles River Laboratories International has a total shareholder equity of $3.7B and total debt of $2.6B, which brings its debt-to-equity ratio to 71.7%. Its total assets and total liabilities are $8.2B and $4.5B respectively. Charles River Laboratories International's EBIT is $656.2M making its interest coverage ratio 5. It has cash and short-term investments of $276.8M.
Key information
71.7%
Debt to equity ratio
US$2.62b
Debt
| Interest coverage ratio | 5x |
| Cash | US$276.77m |
| Equity | US$3.66b |
| Total liabilities | US$4.54b |
| Total assets | US$8.20b |
Recent financial health updates
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Recent updates
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance
Nov 02Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
Oct 18Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?
Oct 18Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Oct 04Charles River raised to Buy at Jefferies on prospects for animal studies
Sep 30Financial Position Analysis
Short Term Liabilities: CRL's short term assets ($1.6B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: CRL's short term assets ($1.6B) do not cover its long term liabilities ($3.5B).
Debt to Equity History and Analysis
Debt Level: CRL's net debt to equity ratio (64.2%) is considered high.
Reducing Debt: CRL's debt to equity ratio has reduced from 122.3% to 71.7% over the past 5 years.
Debt Coverage: CRL's debt is well covered by operating cash flow (26.1%).
Interest Coverage: CRL's interest payments on its debt are well covered by EBIT (5x coverage).